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Background
Ranibizumab (Lucentis®) is an antibody fragment with
high binding affinity for all isoforms of Vascular
Endothelial Growth Factor A (VEGF-A) and is specifi-
cally developed for intraocular use. Since its introduc-
tion in 2007 it has been administered increasingly and
in our hospital approximately 1650 intravitreal injections
were given in 2013. Ranibizumab is injected monthly
and in most patients for a prolonged period of time.
During the procedure several ophthalmic solutions are
used, such as local anaesthetic, disinfection, mydriatic
drugs and antibiotics.
Methods
From March 2012 to January 2014, 15 patients who devel-
oped a skin reaction around the eye after intravitreal injec-
tion were tested. Patch testing and readings were
performed according to the ICDRG criteria. All patients
were patch tested with the Belgian standard series, cos-
metic, pharmaceutical and ophthalmic series. All eyedrops
used during the intravitreal injection procedure were tested.
Ranibizumab could not be tested because it is expensive.
Results
Of the 15 patients referred for patch testing 47% were
females, the mean age of the patients was 70 years
(range 49-87). All patients described a similar reaction
pattern, i.e. a burning and stinging sensation, redness
and swelling, in the majority of cases starting within 12
hours after the injection. The mean number of injec-
tions before a reaction occurred was 12. Eight patients
tested positive for phenylephrine (=PE) hydrochloride
10% aqua (of which 2 also reacted to Tobrex and
another 2 to Isobetadine oculaire), 2 patients reacted to
sodiummetabisulfite (a preservative in Phenylephrine
Minims) and 1 patient only had a positive test for Phe-
nylephrine Minims. In 2 patients there was only one
positive test for Isobetadine oculaire, in 2 patients all
tests were negative.
Conclusion
In the last two years there has been a steep rise in the
number of patients with suspected contact dermatitis
after injection with ranibizumab. The most common
relevant allergen was PE, being positive in 60% of the
patients. We hypothesize that patients become sensitized
because of the high frequency with which PE is used.
The rise in referrals is also due to the fact that the
ophthalmologists in our hospital are aware of the pro-
blem. In literature PE has been found to be a frequent
cause of contact dermatitis [1].
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